Back

Effects of the chymase inhibitor fulacimstat on adverse cardiac remodelling after acute myocardial infarction - Results of the CHIARA MIA 2 trial

31 August 2019 (09:36 - 09:54)
Organised by:
Congress Presentation Part of: New strategies in acute coronary syndrome management Left Ventricular Remodelling ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Hans-Dirk Duengen

Scirent - Clinical Research and Science, Berlin (Germany)

4 More presentations in this session

Presentation thumbnail
Unanswered questions in acute coronary syndromes: do we know enough in 2019?
Professor K. Fox (Edinburgh, GB)
Slides Video
Presentation thumbnail
Coronary CT angiography as the first-line diagnostic strategy in patients with Non-ST-segment Elevation Acute Coronary Syndrome - The VERDICT trial
Associate Professor K. Kofoed (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Oxygen therapy in myocardial infarction patients with or without diabetes mellitus - A predefined subgroup analysis from the DETO2X-AMI trial
Doctor R. Hofmann (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
What do we do for patients not adressed in guidelines?
Doctor R. Califf (Durham, US)
Slides Video

Access the full session

Session thumbnail
New strategies in acute coronary syndrome management

The Event

Event poster

ESC Congress 2019

31 August 2019 09:36 CET
You may be interested in
thumbnail
Congress Presentation
Assessement of left ventricular mechanical dispersion and global longitudinal strain in prognosis of adverse cardiac remodeling in patients after ST-segment elevation myocardial infarction
thumbnail
Congress Presentation
Identifying biomarkers and establishing their threshold values concordantly with LV remodeling for predicting long-term MACE following STEMI
thumbnail
Congress Presentation
Vitamin D supplements do not affect adverse left ventricular remodelling after an anterior myocardial infarction

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources